OBJECTIVE: To evaluate the relative cost-effectiveness in different sub-Saharan African settings of presumptive treatment, field-standard microscopy and rapid diagnostic tests (RDTs) to diagnose malaria. METHODS: We used a decision tree model and probabilistic sensitivity analysis applied to outpatients presenting at rural health facilities with suspected malaria. Costs and effects encompassed those for both patients positive on RDT (assuming artemisinin-based combination therapy) and febrile patients negative on RDT (assuming antibiotic treatment). Interventions were defined as cost-effective if they were less costly and more effective or had an incremental cost per disability-adjusted life year averted of less than US$ 150. Data were drawn from published and unpublished sources, supplemented with expert opinion. FINDINGS: RDTs were cost-effective compared with presumptive treatment up to high prevalences of Plasmodium falciparum parasitaemia. Decision-makers can be at least 50% confident of this result below 81% malaria prevalence, and 95% confident below 62% prevalence, a level seldom exceeded in practice. RDTs were more than 50% likely to be cost-saving below 58% prevalence. Relative to microscopy, RDTs were more than 85% likely to be cost-effective across all prevalence levels, reflecting their expected better accuracy under real-life conditions. Results were robust to extensive sensitivity analysis. The cost-effectiveness of RDTs mainly reflected improved treatment and health outcomes for non-malarial febrile illness, plus savings in antimalarial drug costs. Results were dependent on the assumption that prescribers used test results to guide treatment decisions. CONCLUSION: RDTs have the potential to be cost-effective in most parts of sub-Saharan Africa. Appropriate management of malaria and non-malarial febrile illnesses is required to reap the full benefits of these tests.
OBJECTIVE: To evaluate the relative cost-effectiveness in different sub-Saharan African settings of presumptive treatment, field-standard microscopy and rapid diagnostic tests (RDTs) to diagnose malaria. METHODS: We used a decision tree model and probabilistic sensitivity analysis applied to outpatients presenting at rural health facilities with suspected malaria. Costs and effects encompassed those for both patients positive on RDT (assuming artemisinin-based combination therapy) and febrile patients negative on RDT (assuming antibiotic treatment). Interventions were defined as cost-effective if they were less costly and more effective or had an incremental cost per disability-adjusted life year averted of less than US$ 150. Data were drawn from published and unpublished sources, supplemented with expert opinion. FINDINGS:RDTs were cost-effective compared with presumptive treatment up to high prevalences of Plasmodium falciparum parasitaemia. Decision-makers can be at least 50% confident of this result below 81% malaria prevalence, and 95% confident below 62% prevalence, a level seldom exceeded in practice. RDTs were more than 50% likely to be cost-saving below 58% prevalence. Relative to microscopy, RDTs were more than 85% likely to be cost-effective across all prevalence levels, reflecting their expected better accuracy under real-life conditions. Results were robust to extensive sensitivity analysis. The cost-effectiveness of RDTs mainly reflected improved treatment and health outcomes for non-malarial febrile illness, plus savings in antimalarial drug costs. Results were dependent on the assumption that prescribers used test results to guide treatment decisions. CONCLUSION:RDTs have the potential to be cost-effective in most parts of sub-Saharan Africa. Appropriate management of malaria and non-malarial febrile illnesses is required to reap the full benefits of these tests.
Authors: Maria E Rafael; Terrie Taylor; Alan Magill; Yee-Wei Lim; Federico Girosi; Richard Allan Journal: Nature Date: 2006-11-23 Impact factor: 49.962
Authors: James A Berkley; Kathryn Maitland; Isaiah Mwangi; Caroline Ngetsa; Saleem Mwarumba; Brett S Lowe; Charles R J C Newton; Kevin Marsh; J Anthony G Scott; Mike English Journal: BMJ Date: 2005-03-29
Authors: James A Berkley; Brett S Lowe; Isaiah Mwangi; Thomas Williams; Evasius Bauni; Saleem Mwarumba; Caroline Ngetsa; Mary P E Slack; Sally Njenga; C Anthony Hart; Kathryn Maitland; Mike English; Kevin Marsh; J Anthony G Scott Journal: N Engl J Med Date: 2005-01-06 Impact factor: 91.245
Authors: Melita A Gordon; Hastings T Banda; Macpherson Gondwe; Stephen B Gordon; Martin J Boeree; Amanda L Walsh; John E Corkill; C Anthony Hart; Charles F Gilks; Malcolm E Molyneux Journal: AIDS Date: 2002-08-16 Impact factor: 4.177
Authors: M H Craig; B L Bredenkamp; C H Vaughan Williams; E J Rossouw; V J Kelly; I Kleinschmidt; A Martineau; G F J Henry Journal: Trans R Soc Trop Med Hyg Date: 2002 May-Jun Impact factor: 2.184
Authors: Peter W Gething; Viola C Kirui; Victor A Alegana; Emelda A Okiro; Abdisalan M Noor; Robert W Snow Journal: PLoS Med Date: 2010-07-06 Impact factor: 11.069
Authors: Benjamin S C Uzochukwu; Eric N Obikeze; Obinna E Onwujekwe; Chima A Onoka; Ulla K Griffiths Journal: Malar J Date: 2009-11-23 Impact factor: 2.979
Authors: Suerie Moon; Carmen Pérez Casas; Jean-Marie Kindermans; Martin de Smet; Tido von Schoen-Angerer Journal: PLoS Med Date: 2009-07-21 Impact factor: 11.069